A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes | MicrobiomeTrials
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2024-05-30Est. Completion: 2026-02-03
Enrollment target: 115 participants
Locations
East Sydney Doctors, Darlinghurst, New South Wales, Australia
Canopy Clinical Sutherland, Miranda, New South Wales, Australia
Momentum Clinical Research, Sydney, New South Wales, Australia
Canopy Beaches Clinical Research, Sydney, New South Wales, Australia
Canopy Clinical Wollongong, Wollongong, New South Wales, Australia
Momentum Sunshine, Melbourne, Victoria, Australia
Royal Melbourne Hospital, Parkville, Victoria, Australia
New Zealand Clinical Research, Auckland, New Zealand
New Zealand Clinical Research Christchurch, Christchurch, New Zealand
Pacific Clinical Research Network - Hamilton, Hamilton, New Zealand
Pacific Clinical Research Network - Tasman, Nelson, New Zealand
Momentum Palmerston North, Palmerston North, New Zealand
Pacific Clinical Research Network - Rotorua, Rotorua, New Zealand
Pacific Clinical Research Network - Wellington, Upper Hutt, New Zealand
Momentum Kapiti, Waikanae, New Zealand
Other microbiome trials you might be interested in